Despite COVID-19 workarounds, such as telehealth and virtual recovery programs enabled by flexible federal guidelines, more than 40 states have reported increases in drug overdoses during the pandemic, underscoring the importance of keeping state harm reduction programs as accessible as possible. As COVID-19 upends the nation’s health care systems, treatment for substance use disorder (SUD) […]
Author Archive for: eliza-mette
About Eliza Mette
Eliza Mette joined NASHP in June 2019 as a policy associate on the Chronic and Vulnerable Populations team. Prior to joining NASHP, Eliza practiced as a health care attorney at Kozak & Gayer, a health care law firm in Augusta, Maine. Eliza also served as a Cancer Research Training Award Fellow with the National Cancer Institute where she focused on global health, health disparities, and metabolomics, all within the context of cancer research. Eliza graduated cum laude from the George Washington University with a BS in public health and magna cum laude from the University of Maine School of Law.
Entries by Eliza Mette
As drug overdose fatalities continue to rise and incarceration rates remain high nationwide despite recent declines, states are increasingly developing opportunities for incarcerated individuals to access evidence-based opioid use disorder (OUD) treatment in state prison facilities. While the forced abstinence during incarceration can temporarily pause substance use itself, providing comprehensive treatment that includes medications for […]
The National Academy for State Health Policy (NASHP) recently spoke to Robert Hansen, executive director of West Virginia’s Office of Drug Control Policy, to learn how the state is expanding opioid use disorder (OUD) treatment access and capacity through strategic partnerships that support its Substance Use Response Plan’s goals. West Virginia has made expanding access […]
People with substance use disorders (SUD) who are experiencing housing instability or homelessness are particularly at risk during the COVID-19 pandemic, leaving states challenged more than ever to identify effective housing strategies that can simultaneously address the complex treatment needs of people with SUD while also curbing the spread of COVID-19 in congregate settings.
The COVID-19 pandemic poses unique risks to people with opioid use disorder (OUD). Overdose risk increases when using individuals are in isolation and injection drug users are at higher risk of COVID-19 mortality due to increased rates of other infectious diseases and negative health effects from substance use.
State Medicaid home- and community-based waivers and state plan amendments can provide critical information, counseling, and training to family caregivers. Recently, the National Academy for State Health Policy (NASHP) reviewed states’ Medicaid 1915(c) and 1115 waivers, and 1915(i) and 1915(j) state plan amendments (SPAs) that focuses on waivers and state plan amendments covering older adults […]
In response to an increase in HIV and hepatitis C virus (HCV) infections in individuals with substance use disorders (SUD), including opioid use disorders (OUD), state policymakers are employing multifaceted strategies to address this syndemic, collaborating with public and private partners to prevent the spread of infectious disease and provide access to evidence-based treatment. This report […]
States are turning to telehealth to minimize direct contact between patients, providers, and other staff during the COVID-19 pandemic. For opioid use disorder (OUD) treatment, this shift represents a significant departure from how these services have been historically delivered and requires rapid organizational changes.
As coronavirus (COVID-19) cases increase exponentially and containment measures expand across the country, another public health emergency – the opioid use disorder (OUD) crisis – continues to rage. For individuals in treatment for OUD and those who provide them, COVID-19 presents a new set of barriers that make accessing these critical services challenging.